IRIS
RICEVUTO, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.255
EU - Europa 3.528
AS - Asia 1.667
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 6
AF - Africa 1
Totale 10.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.241
IE - Irlanda 1.077
CN - Cina 854
TR - Turchia 673
SE - Svezia 604
DE - Germania 421
IT - Italia 412
UA - Ucraina 331
GB - Regno Unito 280
FI - Finlandia 162
FR - Francia 141
SG - Singapore 75
CZ - Repubblica Ceca 41
IN - India 27
VN - Vietnam 24
BE - Belgio 22
CA - Canada 7
AU - Australia 6
EU - Europa 6
NL - Olanda 6
DM - Dominica 5
KR - Corea 5
ES - Italia 4
AT - Austria 3
BR - Brasile 3
LU - Lussemburgo 3
RO - Romania 3
RS - Serbia 3
RU - Federazione Russa 3
CL - Cile 2
EE - Estonia 2
JP - Giappone 2
MX - Messico 2
PT - Portogallo 2
BD - Bangladesh 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
DK - Danimarca 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PL - Polonia 1
SA - Arabia Saudita 1
TH - Thailandia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 10.470
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.308
Chandler 1.216
Dublin 1.077
Izmir 326
Boardman 238
Nanjing 236
Wilmington 194
San Mateo 191
Lawrence 168
Princeton 168
Ann Arbor 164
Ashburn 118
New York 117
Beijing 106
Nanchang 86
Milan 83
Woodbridge 74
Bremen 61
Seattle 57
Shenyang 56
Tianjin 54
Singapore 53
Des Moines 47
Hebei 44
L'aquila 43
Verona 43
Brno 40
Kunming 37
Changsha 31
Jiaxing 29
Sant'egidio Alla Vibrata 27
Mountain View 26
Helsinki 23
Los Angeles 23
Brussels 22
Dong Ket 22
Hangzhou 21
Jinan 21
Norwalk 21
Dearborn 19
Philadelphia 19
Zhengzhou 17
Guangzhou 16
Munich 16
Pune 16
Auburn Hills 15
Shanghai 13
Lanzhou 12
Ningbo 12
Pescara 12
Changchun 11
Dallas 11
Falls Church 11
Monza 10
Fremont 8
Fuzhou 8
Taizhou 8
L’Aquila 7
Redwood City 7
Rome 7
Tappahannock 7
Berlin 6
London 6
Washington 6
Buffalo 5
Melzo 5
Roseau 5
San Francisco 5
Clifton 4
Düsseldorf 4
Hefei 4
Madrid 4
Toronto 4
Baotou 3
Campobasso 3
Ciampino 3
Frankfurt am Main 3
Grafing 3
Melbourne 3
Orange 3
Phoenix 3
Vienna 3
Amsterdam 2
Aquila 2
Belgrade 2
Borås 2
Caserta 2
Catanzaro 2
Hanoi 2
Hanover 2
Houston 2
Luxembourg 2
Messina 2
Napoli 2
Qingdao 2
Shaoxing 2
Strasbourg 2
Tallinn 2
Tarcento 2
Trestina 2
Totale 7.054
Salva come PNG Salva come JPEG
Nome #
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer 108
Mutazioni della p53 in campioni selezionati di adenocarcinoma del colon dell’Italia Centrale 100
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 99
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 98
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 98
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 96
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 95
A gene expression signature from bone metastases as predictor of clinical outcome in breast cancer patients 92
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 92
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families 90
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer 89
Antiproliferative and pro-apoptotic effects of 5-azacytidine in prostate carcinoma cells in vitro involve the recovering of PTEN-mediated Akt activity control and androgen sensitivity 89
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro 88
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line 85
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 85
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer 84
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 83
Assessment and treatment of symptoms among italian medical oncologists 81
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 81
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 81
Trifluoroibuprofen inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in Vivo Tumor Growth in Aggressive Prostate Cancer Models. 80
The supportive care task force at the University of L'Aquila: 2-years experience 80
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer. families 79
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 79
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 79
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 78
ABERRANT HYPERMETHYLATION OF THE P16 GENE IN SPORADIC GASTRIC CANCER 77
Symptoms in advanced cancer: The influence of sex, age, Karnofsky Performance Status and PaP score. 77
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells 77
Oncology together for L'Aquila: early resumption of integrated oncological activities after the earthquake 76
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models 76
NEW MUTATIONS AND PROTEIC VARIANTS OF NBS1 ARE IDENTIFIED IN CANCER CELL LINES 75
A KRAS and dual concomitant PI3KCA mutations in a metastatic colorectal cancer patient with aggressive and resistant disease 75
Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab 75
Oxaliplatin (l-OHP) association with paclitaxel (PTX) or docetaxel (DTX) in NSCLC cell lines: Schedule-dependent activity based on p53/microtubule associated protein 4 (MAP4) interaction 75
An association of epirubicin, etoposide and cisplatin in gastric cancer: a phase II study 74
Pain evaluation and management: a survey of Italian radiotherapists 74
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer 73
Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: A retrospective study 73
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 72
Poker association of weekly alternating 5-fluorouracil, irinotecan,bevacizumab and oxaliplatin (FIrB/FOx) in first line treatment of metastatic colorectal cancer: a phase II study 71
Role of estrogen receptor alpha in aggressiveness and osteoclastogenic potential of human breast carcinoma cells. 70
A six-gene signature predicting breast cancer lung metastasis 70
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases 70
Meccanismo d’azione e farmacologia di nuovi composti organometallici nel trattamento del carcinoma del colon-retto. 69
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients 69
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 69
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro 68
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 68
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 68
Role of immunoscintigraphy in clinical assessment of gastrointestinal tumors 68
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 68
Novel P53 mutations detected by FAMA in colorectal cancers 67
Plasma proteomic profiling in hereditary breast cancer reveals a BRCA1-specific signature: Diagnostic and functional implications 67
Does the search for large genomic rearrangements impact BRCAPRO carrier prediction? 66
Multidisciplinary management of hepatocellular carcinoma in clinical practice 66
New mutations and protein variants of NBSI are identified in cancer cell lines 65
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. 65
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 65
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models 65
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study 65
Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma? 65
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 65
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 65
The adjuvant therapy of colonic carcinoma in old age 64
Prognosis of gastric cancer by p53 gene mutations from "touch preparations" and PCR/SSCP analysis. 64
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 64
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models 63
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations 63
Medical emergencies in oncology: hypercalcemia. II. Diagnosisand therapy 63
Carcinoma della vescica 63
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 63
Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease 63
Prognosis of gastric cancer by p53 gene mutations from "touch preparations" and PCR/SSCP analysis. 63
Significato prognostico e predittivo delle alterazioni genetiche nel carcinoma gastrico 62
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, Fir-B/FOx, according to seconde-line treatment and KRAS genotype 62
Awareness of disease severity in Italian breast cancer patients submitted to mastectomy or conservative surgery 62
Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients 62
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 62
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts 62
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study 62
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study 62
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study 61
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama 61
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 61
From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters 61
Recidive loco-regionali da carcinoma colo-rettale: risultati a breve termine della perfusione pelvica ipossica. 61
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen 61
A set of genes expressed in breast cancer bone metastases discloses predisposition to generate metastases in multiple organs 60
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy 60
Valutazioni seriate del peptide natriuretico cerebrale sono predittive di cardiotossicità da antracicline in pazienti sottoposti a chemioterapia non ad alte dosi 60
Familiarity and heredity of tumors in function of an early surgical therapeutic approach 60
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 60
Oxaliplatin:preclinical in vitro studies 60
Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer 59
Intraperitoneal chemotherapy [LA CHEMIOTERAPIA INTRAPERITONEALE] 59
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models 59
Carcinoma della pelvi renale e dell'uretere 59
Choice of chemotherapy schedules in elderly patients (> 75 years) with metastatic colorectal cancer (mcrc) according to comorbidity 59
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 59
Totale 7.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.175 0 39 174 10 6 204 289 22 203 42 7 179
2020/20211.451 20 173 8 178 190 70 186 10 178 68 283 87
2021/20221.110 67 88 276 73 32 18 12 55 66 21 76 326
2022/20233.321 233 205 61 358 346 378 5 212 1.375 13 78 57
2023/2024717 116 44 33 103 50 178 16 63 0 28 27 59
2024/2025138 97 41 0 0 0 0 0 0 0 0 0 0
Totale 10.694